Ask AI
ProCE Banner Activity

CNS-Active Systemic Therapy for HER2-Positive Breast Cancer

Slideset

Explore CNS-active systemic therapy for HER2-positive breast cancer with brain metastases, including intracranial efficacy and safety evidence for antibody–drug conjugates and tucatinib-based regimens. Review how disease context and local therapy needs inform treatment selection and sequencing.

Released: November 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This educational activity is intended for neuro-oncologists, oncologists, and other multidisciplinary healthcare professionals involved in the care of individuals with breast cancer brain metastases.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply intracranial efficacy and safety data from clinical trials of antibody-drug conjugates and other CNS-active systemic therapies to select and sequence treatment for patients with breast cancer brain metastases

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.